{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:08:13Z","timestamp":1780085293559,"version":"3.54.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"DOI":"10.1186\/s12981-024-00680-x","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T15:59:02Z","timestamp":1732723142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Brief communication: efficacy and safety of the dolutegravir\/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIV"],"prefix":"10.1186","volume":"21","author":[{"given":"Zhenyan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinzhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangkai","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuibao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"issue":"1","key":"680_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","volume":"36","author":"P Cahn","year":"2022","unstructured":"Cahn P, Sierra Madero J, Arribas JR, Antinori A, Ortiz R, Clarke AE, et al. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection. AIDS. 2022;36(1):39\u201348.","journal-title":"AIDS"},{"issue":"4","key":"680_CR2","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/cid\/ciac130","volume":"76","author":"JM Llibre","year":"2023","unstructured":"Llibre JM, Brites C, Cheng CY, Osiyemi O, Galera C, Hocqueloux L, et al. Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial. Clin Infect Dis. 2023;76(4):720\u20139.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"680_CR3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/cid\/ciac036","volume":"75","author":"O Osiyemi","year":"2022","unstructured":"Osiyemi O, De Wit S, Ajana F, Bisshop F, Portilla J, Routy JP, et al. Efficacy and safety of switching to dolutegravir\/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the phase 3, noninferiority TANGO randomized trial. Clin Infect Dis. 2022;75(6):975\u201386.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"680_CR4","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"J van Wyk","year":"2020","unstructured":"van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla Sogorb J, et al. Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020;71(8):1920\u20139.","journal-title":"Clin Infect Dis"},{"key":"680_CR5","unstructured":"EACS Guidelines version 12.0, October 2023. https:\/\/www.eacsociety.org\/media\/guidelines-12.0.pdf. Accessed 15 Sep 2024."},{"key":"680_CR6","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. Department of Health and Human Services. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv. Accessed 15 Sept 2024."},{"key":"680_CR7","unstructured":"Update on the transition to dolutegravir-based antiretroviral therapy: report of a WHO meeting, 29\u201330 March 2022. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO."},{"issue":"1","key":"680_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11904-019-00478-x","volume":"17","author":"W Cao","year":"2020","unstructured":"Cao W, Hsieh E, Li T. Optimizing treatment for adults with HIV\/AIDS in China: successes over two decades and remaining challenges. Curr HIV\/AIDS Rep. 2020;17(1):26\u201334.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"12","key":"680_CR9","first-page":"1106","volume":"60","author":"AAHCPG S","year":"2021","unstructured":"AAHCPG S. Chinese guidelines for diagnosis and treatment of HIV\/AIDS (2021 edition). Zhonghua Nei Ke Za Zhi. 2021;60(12):1106\u201328.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"680_CR10","doi-asserted-by":"publisher","first-page":"04078","DOI":"10.7189\/jogh.14.04078","volume":"14","author":"S Zhu","year":"2024","unstructured":"Zhu S, Wang W, He J, Duan W, Ma X, Guan H, et al. Higher cardiovascular disease risks in people living with HIV: a systematic review and meta-analysis. J Glob Health. 2024;14:04078.","journal-title":"J Glob Health"},{"issue":"1","key":"680_CR11","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1186\/s12879-023-08587-0","volume":"23","author":"X Li","year":"2023","unstructured":"Li X, Song X, Han Y, Qiu Z, Cao W, Li T. Risk factors and longitudinal changes of dyslipidemia among Chinese people living with HIV receiving antiretroviral therapy. BMC Infect Dis. 2023;23(1):598.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"680_CR12","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1093\/jac\/dkv494","volume":"71","author":"L Calza","year":"2016","unstructured":"Calza L, Colangeli V, Manfredi R, Bon I, Re MC, Viale P. Clinical management of dyslipidaemia associated with combination antiretroviral therapy in PLWH. J Antimicrob Chemother. 2016;71(6):1451\u201365.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"680_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/cid\/civ296","volume":"61","author":"JR Santos","year":"2015","unstructured":"Santos JR, Saumoy M, Curran A, Bravo I, Llibre JM, Navarro J, et al. The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61(3):403\u20138.","journal-title":"Clin Infect Dis"},{"key":"680_CR14","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.2147\/IDR.S451346","volume":"17","author":"M Deng","year":"2024","unstructured":"Deng M, Chen N, Lao X, Wang X, Fu J, Xing L, et al. Reasons, efficacy and safety of switching to dolutegravir-based regimens among virologically suppressed PLWH: a retrospective cohort study of 96 weeks. Infect Drug Resist. 2024;17:1571\u201382.","journal-title":"Infect Drug Resist"},{"key":"680_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.33393\/dti.2023.2529","volume":"17","author":"S Khemla","year":"2023","unstructured":"Khemla S, Meesing A, Sribenjalux W, Chetchotisakd P. Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir. Drug Target Insights. 2023;17:45\u201353.","journal-title":"Drug Target Insights"},{"issue":"5","key":"680_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/QAD.0000000000000103","volume":"28","author":"JC Yombi","year":"2014","unstructured":"Yombi JC, Pozniak A, Boffito M, Jones R, Khoo S, Levy J, et al. Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity. AIDS. 2014;28(5):621\u201332.","journal-title":"AIDS"},{"issue":"3","key":"680_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/QAD.0000000000003434","volume":"37","author":"E Mondesert","year":"2023","unstructured":"Mondesert E, Reynes J, Makinson A, Bargnoux AS, Plawecki M, Morquin D, et al. Cystatin C in addition to creatinine for better assessment of glomerular renal function decline in people with HIV receiving antiretroviral therapy. AIDS. 2023;37(3):447\u201354.","journal-title":"AIDS"},{"issue":"1","key":"680_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1186\/s12891-022-05438-y","volume":"23","author":"J Shu","year":"2022","unstructured":"Shu J, Tan A, Li Y, Huang H, Yang J. The correlation between serum total alkaline phosphatase and bone mineral density in young adults. BMC Musculoskelet Disord. 2022;23(1):467.","journal-title":"BMC Musculoskelet Disord"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-024-00680-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-024-00680-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-024-00680-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T16:06:40Z","timestamp":1732723600000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-024-00680-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["680"],"URL":"https:\/\/doi.org\/10.1186\/s12981-024-00680-x","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Ethics Committee of SPHCC (2020-S197-02). Informed consent was waived for data collected retrospectively.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}